Financial Performance - The company reported a total revenue of RMB 500 million for the year 2020, representing a year-on-year increase of 15%[12]. - The net profit attributable to shareholders was RMB 80 million, which is a 10% increase compared to the previous year[12]. - The company's operating revenue for 2020 was ¥647,691,188.74, representing a 9.40% increase compared to ¥592,058,026.89 in 2019[6]. - The net profit attributable to shareholders for 2020 was ¥12,924,662.58, a significant decrease of 78.53% from ¥60,199,518.00 in 2019[6]. - The total profit amounted to RMB 28.76 million, a decrease of 61.87% year-on-year[52]. - The net profit after deducting non-recurring gains and losses was ¥8,489,349.07, down 85.13% from ¥57,086,493.85 in 2019[6]. - The net cash flow from operating activities decreased by 23.24% to ¥56,472,415.67 from ¥73,571,356.00 in 2019[6]. - The total assets at the end of 2020 were ¥1,185,934,827.59, an increase of 56.77% from ¥756,494,685.39 at the end of 2019[6]. Strategic Plans and Investments - The company plans to invest RMB 50 million in research and development for new product lines in 2021[12]. - The management has set a revenue target of RMB 600 million for 2021, reflecting a growth rate of 20%[12]. - The company is focusing on the medical health industry, particularly in the field of precision radiation therapy for tumors, with plans to establish specialized hospitals in major cities[26]. - The company aims to enhance its industry foundation through investments and acquisitions, adopting a model of "internal growth + external mergers" to expand its market presence[27]. - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[12]. - The company has successfully acquired Dazhou Medical Oncology Hospital and Kunming Medical Oncology Hospital, and has established Chongqing Huapu Oncology Hospital, marking a strong start to its strategic transformation[33]. - The company aims to build a nationwide oncology medical service network, focusing on radiation therapy, to capture a larger market share in the growing sector[33]. Market Expansion and User Growth - User data indicates a growth in active users by 25%, reaching a total of 1 million users by the end of 2020[12]. - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 20% market share by 2023[12]. - The company has expanded its market presence in Southeast Asia, the Middle East, and South America, moving beyond its traditional markets in Europe and the US[55]. Risks and Challenges - The company has identified policy risks and goodwill impairment risks as significant factors affecting future performance[5]. - The aging population in China is leading to an increase in cancer incidence, with projections indicating that annual cancer cases will rise from approximately 4.4 million in 2019 to about 5.11 million by 2025[28]. - The company faces industry policy risks that may impact its ability to expand in the domestic market due to potential tightening of regulations on private medical investments[117]. - There is a risk of delayed reimbursement from local medical insurance, which could increase as the scale of hospital operations expands[118]. - The company is exposed to foreign exchange risks due to its reliance on exports, primarily settled in USD, and has implemented a pricing mechanism to mitigate this risk[121]. Research and Development - The company continues to focus on enhancing its intelligent control technology to improve product efficiency and customer satisfaction[12]. - The company has invested in Dazhou Medical Oncology Hospital, Kunming Medical Oncology Hospital, and holds shares in Xi'an Medical Oncology Hospital, focusing on precision radiation therapy[66]. - The company has implemented a multi-level incentive mechanism to attract and retain talent in the medical field, enhancing its operational capabilities[56]. - The company’s R&D expenses decreased by 24.35% to ¥14,058,334.55, representing 2.17% of operating revenue[73]. - The number of R&D personnel increased by 11.54% to 87, although the proportion of R&D personnel decreased to 8.42%[73]. Financial Management and Governance - The company raised a total of RMB 37,125.00 million from the public offering of 25 million shares at RMB 14.85 per share, with a net amount of RMB 32,821.27 million after deducting issuance costs of RMB 4,303.73 million[97]. - As of the end of the reporting period, the company had cumulatively used RMB 34,720.17 million of the raised funds, with RMB 2,936.15 million used during the reporting period[99]. - The company has no idle funds that have been unused for over two years[99]. - The company has committed to not occupying the funds or assets of the listed company and to minimize related party transactions, ensuring fairness and normal commercial conditions[133]. - The company has established a commitment to minimize related party transactions and ensure they are conducted under fair and reasonable commercial terms[138]. Compliance and Legal Matters - The company has not faced any major litigation or arbitration matters during the reporting period, reflecting a stable legal environment[156]. - The company has not experienced any penalties or rectification situations during the reporting period, indicating compliance with regulations[157]. - The company has not reported any non-compliance with commitments made regarding the waiver of voting rights[145]. Corporate Changes and Shareholder Commitments - The company changed its corporate type from "joint-stock company (Taiwan, Hong Kong, Macao and domestic joint venture, listed)" to "joint-stock company (listed)"[189]. - The controlling shareholder increased its stake by acquiring between 1.9 million and 2 million shares, representing approximately 0.9536% of the total share capital[190]. - The company plans to reduce its shareholding by no more than 25% of the total shares held during the 24 months following the expiration of the lock-up period[137]. - The company has completed its share reduction commitments as of the reporting period, with no shares held by certain stakeholders[138].

永和流体智控股份有限公司 2020 年第三季度报告全文 永和流体智控股份有限公司 2020 年第三季度报告 2020 年 10 月 1 永和流体智控股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曹德莅、主管会计工作负责人廖丽娜及会计机构负责人(会计主管人员)廖丽 娜声明：保证季度报告中财务报表的真实、准确、完整。 2 永和流体智控股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年 | | --- | --- | --- | --- | --- | | | | | | 度末增减 | | 总资产（元） | 1,121,751,747.77 | | 756,494,685.39 | 48.28% | | 归属于上市公司股东的净资产（元） ...

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 304,240,690.74, representing a 1.07% increase compared to CNY 301,015,681.21 in the same period last year[17]. - The net profit attributable to shareholders decreased by 22.31% to CNY 29,604,594.62 from CNY 38,106,430.13 year-on-year[17]. - The net cash flow from operating activities dropped significantly by 65.02%, amounting to CNY 27,843,865.47 compared to CNY 79,597,519.54 in the previous year[17]. - Basic earnings per share decreased by 21.05% to CNY 0.15 from CNY 0.19 in the same period last year[17]. - The weighted average return on net assets was 4.75%, down 0.56 percentage points from 5.31% in the previous year[17]. - The company reported a significant increase in management expenses by 70.02% to ¥31,345,928.50, primarily due to the expansion of its medical business[46]. - Research and development investment decreased by 35.99% to ¥5,955,045.63, reflecting a reduction in R&D activities[46]. - The company reported a financial expense of CNY 3,048,342.84, compared to a financial income of CNY 3,163,020.22 in the same period last year[169]. - The total profit for the first half of 2020 was CNY 39,086,510.64, down 14.7% from CNY 45,873,467.61 in the same period of 2019[171]. Assets and Liabilities - The total assets of the company increased by 38.83% to CNY 1,050,243,924.52 from CNY 756,494,685.39 at the end of the previous year[17]. - The total liabilities rose to CNY 410,256,288.00 from CNY 148,271,693.97, marking an increase of approximately 176.5%[163]. - Non-current assets increased to CNY 612,483,321.62 from CNY 257,232,227.79, a growth of about 138.5%[162]. - The company's equity attributable to shareholders rose to CNY 637,814,129.15 from CNY 608,222,991.42, an increase of approximately 4.8%[164]. - The total liabilities to equity ratio increased significantly, indicating a higher leverage position for the company[163]. Strategic Expansion - The company is expanding into the medical health industry, focusing on tumor precision radiation therapy and establishing specialized hospitals in key cities[25][26]. - The company has established a dual-industry strategy of "medical health industry + fluid control business" to enhance its comprehensive strength and profitability[25][32]. - The company has actively expanded into the medical health industry, acquiring Dazhou Medical Oncology Hospital and investing in Chongqing Huapu Oncology Hospital[40]. - The company aims to achieve chain and scale operations for oncology specialty hospitals in key domestic cities through both organic growth and acquisitions[40]. - The company is strategically transitioning towards the healthcare industry, focusing on precision radiation therapy for tumors, in response to complex international economic conditions and trade uncertainties[86]. Investment and Financing - The company plans to leverage capital market financing tools to enhance its financial strength and reduce operational liabilities[42]. - The company reported a net cash inflow from financing activities of ¥104,875,031.34, a 204.88% increase compared to the previous year[46]. - The company has short-term borrowings of ¥180 million, which is a new bank loan for working capital[53]. - The company plans to issue up to 60.36 million CNY in non-public shares at a price of 10.06 CNY per share to its actual controller, with proceeds used for repaying bank loans and supplementing working capital[114]. - The company applied for a comprehensive credit facility totaling up to RMB 600 million to support its development plans and strategic implementation[127]. Risk Management - The company has established a risk management system for foreign exchange hedging, which prohibits speculative and arbitrage trading[70]. - The company plans to actively manage accounts receivable to prevent overdue payments and reduce risks associated with customer defaults[70]. - The company emphasizes the importance of aligning delivery periods with business cycles in its forward foreign exchange transactions[70]. - The cost of copper rods accounts for approximately 60% of the production costs, making copper price fluctuations a significant risk for the company[90]. - The company exports over 90% of its valve and pipe products, primarily priced in USD, exposing it to RMB exchange rate risks[91]. Corporate Governance - The financial report was approved by the board of directors on August 24, 2020, ensuring governance compliance[199]. - The company has not faced any penalties or rectification issues during the reporting period[106]. - The company has fulfilled its commitments regarding shareholding and voting rights[101]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period[145]. - The company appointed a new financial director, Liao Lina, on August 24, 2020, following the resignation of the previous financial director[154]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,172[142]. - The largest shareholder, Taizhou Yongjian Holdings Co., Ltd., holds 29.00% of the shares, totaling 58,000,000 shares, which are pledged[142]. - The company has a commitment to reduce stock holdings by no more than 5% of total shares each year after the lock-up period[96]. - The unrestricted shares decreased by 22,458,000 shares, resulting in 177,542,000 unrestricted shares, which is 88.77% of total shares[138]. - The company has a commitment to not reduce its shareholding by more than 25% of total shares during the lock-up period[99]. Compliance and Reporting - The financial report for the half-year period has not been audited[159]. - There were no major litigation or arbitration matters during the reporting period[104]. - The company has not reported any significant environmental violations or penalties during the reporting period[123]. - The company has not initiated any poverty alleviation programs or plans for the reporting year[125]. - The company has not engaged in any related party transactions during the reporting period, including asset or equity acquisitions[110][111][112][113].

证券代码：002795 证券简称：永和智控 公告编号：2020-065 永和流体智控股份有限公司 关于参加 2020 年浙江辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者特别是中小投资者的沟通交流、构建和谐投资者关 系、提升公司治理水平，永和流体智控股份有限公司（以下简称"公司"）将参 加由中国证监会浙江监管局、浙江上市公司协会与深圳市全景网络有限公司共同 举办的"凝心聚力 共克时艰"2020 年浙江辖区上市公司投资者网上集体接待日 主题活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 上平台举行，投资者可以登录"全景·路演天下"网站（http://rs.p5w.net） 参与公司本次投资者网上接待日活动。网上互动交流时间为 2020 年 5 月 15 日（星 期五）下午 15:00-17:00。 届时公司总经理鲜中东先生、副总经理兼董事会秘书刘杰先生、财务总监卢 烯权先生及相关工作人员将采用网络远程方式与投资者进行沟通。 欢迎广大投资者积极参与。 ...

Financial Performance - Revenue for Q1 2020 was CNY 130,945,135.99, a decrease of 4.65% compared to CNY 137,327,723.12 in the same period last year[7] - Net profit attributable to shareholders was CNY 7,777,412.59, down 47.15% from CNY 14,714,968.63 year-on-year[7] - Basic and diluted earnings per share were both CNY 0.0389, reflecting a 47.15% decline from CNY 0.0736 in the same quarter last year[7] - The company reported a total comprehensive income of CNY 7,621,261.78, compared to CNY 14,639,718.94 in the same period last year[49] - Operating profit for the first quarter was CNY 11,908,204.32, down 33.5% from CNY 17,935,755.24 in the previous period[48] - The company reported a 66.03% decline in investment income to ¥574,263.17, mainly due to reduced bank wealth management products[16] - The company incurred a financial expense of CNY 1,765,667.35, slightly up from CNY 1,738,943.99[48] - The tax expense for the quarter was CNY 4,127,024.22, an increase from CNY 3,161,727.38 year-over-year[48] Cash Flow - Net cash flow from operating activities decreased by 64.54%, amounting to CNY 15,137,908.87 compared to CNY 42,686,856.38 in the previous year[7] - Cash inflow from operating activities was CNY 182,382,730.79, down from CNY 193,430,741.47 in the previous period[54] - The total cash outflow from operating activities was ¥167,244,821.92, compared to ¥150,743,885.09 in the previous year, indicating an increase of 10.5%[56] - The net cash flow from investing activities was -¥70,721,066.18, a significant decline from -¥17,367,739.98 year-over-year[56] - Cash and cash equivalents at the end of the period were ¥88,611,922.80, down from ¥97,367,844.38 at the end of the previous year[57] - The company experienced a net increase in cash and cash equivalents of -¥20,583,991.36 during the quarter, compared to -¥7,206,468.74 in the previous year[57] Assets and Liabilities - Total assets increased by 4.85% to CNY 793,193,826.04 from CNY 756,494,685.39 at the end of the previous year[7] - Current liabilities increased to CNY 164,407,476.16 from CNY 137,853,778.47, reflecting a rise of 19.2%[40] - The company’s total liabilities amounted to CNY 175,155,271.75, compared to CNY 148,271,693.97, which is an increase of 18.1%[40] - Total current assets decreased from ¥499,262,457.60 at the end of 2019 to ¥386,094,467.89, reflecting a reduction of about 22.6%[38] - The company’s total equity attributable to shareholders reached CNY 608,222,991.42, with retained earnings of CNY 115,728,694.71[68] Shareholder Information - The total number of shareholders at the end of the reporting period was 17,521[11] - The largest shareholder, Taizhou Yongjian Holding Co., Ltd., held 29.00% of the shares, amounting to 58,000,000 shares[11] Investments and Acquisitions - The company completed the acquisition of 95% equity in Dazhou Zhongke for ¥88.6 million, which will be consolidated into the financial statements[21] - The company also acquired 100% equity in Chengdu Shanshuishang Hotel for ¥126 million, which will be included in the consolidated financial statements[23] - The company completed the acquisition of 95% equity in Dazhou Zhongke Oncology Hospital Co., Ltd. on January 20, 2020[25] - The company announced the acquisition of 100% equity in Chengdu Shanshui Shang Hotel Co., Ltd. on April 2, 2020[25] Expenses - Management expenses increased by 38.48% to ¥14,397,469.35 due to new investments in the healthcare industry[16] - Research and development expenses decreased by 46.13% to ¥2,189,109.63, primarily due to reduced investment during the pandemic[16] Other Financial Information - Non-recurring gains and losses totaled CNY 584,322.06, primarily from government subsidies and investment income[8] - The company has ongoing projects in construction valued at CNY 54,177,621.74, down from CNY 60,674,830.00, indicating a decrease of 8.2%[41] - The company has a total of 1,300 million yuan in bank wealth management products, with a 3.00% annualized return[29] - The company has not reported any significant or low-security, illiquid, or non-principal-protected high-risk entrusted financial management situations[29] - The company has not disclosed any derivative investments during the reporting period[30]

Financial Performance - The company's operating revenue for 2019 was approximately ¥592.06 million, a decrease of 8.12% compared to ¥644.37 million in 2018[15] - The net profit attributable to shareholders for 2019 was approximately ¥60.20 million, down 25.98% from ¥81.33 million in 2018[15] - The net cash flow from operating activities decreased by 39.01% to approximately ¥73.57 million in 2019, compared to ¥120.62 million in 2018[15] - Basic earnings per share for 2019 were ¥0.30, a decline of 26.83% from ¥0.41 in 2018[15] - The total assets at the end of 2019 were approximately ¥756.49 million, a slight decrease of 0.19% from ¥757.90 million at the end of 2018[15] - The net assets attributable to shareholders decreased by 6.13% to approximately ¥608.22 million at the end of 2019, down from ¥647.97 million at the end of 2018[15] - The weighted average return on equity for 2019 was 9.98%, down from 12.95% in 2018, a decrease of 2.97 percentage points[15] - The company reported a decrease in net profit after deducting non-recurring gains and losses, which was approximately ¥57.09 million in 2019, down 34.90% from ¥87.70 million in 2018[15] - Total revenue for the year was 592,058,027.89 CNY, with a quarterly breakdown of 137,327,723.12 CNY in Q1, 163,687,958.09 CNY in Q2, 153,516,127.86 CNY in Q3, and 137,526,217.82 CNY in Q4[19] - Net profit attributable to shareholders for the year was 60,698,518.00 CNY, with quarterly figures of 14,714,968.63 CNY in Q1, 23,391,461.50 CNY in Q2, 18,850,455.50 CNY in Q3, and 3,242,632.37 CNY in Q4[19] - The net cash flow from operating activities was 73,571,355.00 CNY for the year, with negative cash flow in Q3 and Q4 of -2,222,064.50 CNY and -3,804,099.04 CNY respectively[19] - The total revenue for 2019 was CNY 592.06 million, a decrease of CNY 5.23 million or 8.12% compared to the previous year[48] - The net profit attributable to shareholders was CNY 60.20 million, down CNY 2.11 million or 25.98% year-on-year[48] - Sales expenses and management expenses increased by CNY 18.33 million compared to the previous year, impacting profit margins[48] Market and Strategic Focus - The company continues to focus on the production of lead-free brass valves and fittings, which aligns with industry trends towards environmental sustainability[31] - The company is actively exploring new markets in South America and Southeast Asia to expand its customer base and develop its own brand[28] - The global demand for plumbing and heating equipment is expected to grow, driven by urbanization and infrastructure investment in emerging markets[30] - The company maintains strategic partnerships with major international brands such as HONEYWELL and WATTS, primarily operating under ODM and OEM models[28] - The company has established a competitive advantage in the domestic market due to its location in Zhejiang Yuhuan, a major manufacturing hub for plumbing products[32] - The company is actively exploring emerging markets in Southeast Asia, the Middle East, and South America to drive future growth[49] - The company plans to expand into new markets, particularly in emerging markets like Russia, to drive sustainable growth[92] - The company aims to enhance its production efficiency through technology upgrades and automation, targeting to become a preferred supplier in the global water and HVAC sectors[92] Investment and Subsidiaries - The company established a wholly-owned subsidiary, Chengdu Yonghe Cheng Medical Technology Co., Ltd., to expand into the healthcare industry[49] - The company established two new subsidiaries in November 2019, expanding its operational footprint[58] - The company established three new subsidiaries in 2019: Chengdu Yonghe Cheng Medical Technology Co., Ltd., Zhejiang Yonghe Zhikong Technology Co., Ltd., and Xiamen Yonghe Medical Oncology Hospital Co., Ltd.[138] - The company completed the acquisition of 95% of Dazhou Zhongke Tumor Hospital Co., Ltd. for RMB 88.6 million, integrating it into the company's operations[176] - Chengdu Yonghe Cheng invested RMB 25.5 million for a 51% stake in Xiamen Yonghe Medical Oncology Hospital Co., Ltd., expanding its healthcare services[175] Risks and Challenges - The company has indicated various risk factors affecting its operations, including raw material price fluctuations and policy risks[5] - The company faces risks from raw material price fluctuations, particularly copper, which constitutes about 60% of production costs[97] - The company is exposed to foreign exchange risks due to 90% of its sales being in USD, and it has mechanisms in place to mitigate these risks[98] - The company reported a significant decline in sales revenue in the U.S. market due to the impact of the U.S.-China trade war, alongside a downturn in the European economy[86] Cash Dividend Policy - The company does not plan to distribute cash dividends or issue bonus shares for the year[5] - The company proposed not to distribute cash dividends for the fiscal year 2019, nor to issue bonus shares or increase capital from reserves[107] - The cash dividend distribution plan for 2019 is subject to approval at the annual shareholders' meeting[107] - The retained earnings will be carried forward for future distribution, with a commitment to prioritize cash dividends for investors[110] - The company has established a transparent decision-making process for its cash dividend policy, ensuring protection of minority shareholders' rights[106] - The company has committed to avoiding related party transactions that could harm the interests of shareholders[114] Governance and Compliance - The company has not reported any significant discrepancies between financial reports prepared under international accounting standards and those under Chinese accounting standards[17] - The company has not made any adjustments to its cash dividend policy during the reporting period[106] - The company has committed to maintaining a prudent approach to its compensation system and any proposed equity incentive conditions[123] - The company will ensure compliance with regulatory requirements regarding compensation measures and will issue supplementary commitments if necessary[123] - The company has implemented measures to stabilize its stock price through potential share repurchases and management purchases[124] Financial Management - The company has significant restricted assets totaling 22,468,993.59, including cash, fixed assets, and intangible assets[71] - The company’s cash flow remains stable and secure, supported by timely and stable sales returns from quality foreign trade clients[45] - The company’s financial assets at fair value increased significantly, with initial investment costs of 175,067,315.25 and a total of 632,067,315.25 at the end of the period[76] - The company has no significant guarantees during the reporting period[154] - The company has no intention of engaging in similar business activities as Yonghe Shares, ensuring no competition and prioritizing Yonghe Shares in investment opportunities[121] Shareholder Structure - The controlling shareholder, Taizhou Yongjian Holdings Co., Ltd., underwent a division, reducing its stake in the company from 38.25% to 29%[165] - The actual controller of the company is Cao Deli, who has been the chairman since the change of control on November 7, 2019[192] - The largest shareholder, Taizhou Yongjian Holdings Co., Ltd., holds 29.00% of the shares, totaling 58,000,000 shares, with a decrease of 18,497,600 shares during the reporting period[189] - The company has a total of 21,495 shareholders, with 18,453 being common stockholders[189] - There are no other shareholders holding more than 10% of the shares, indicating a concentrated ownership structure[193]

证券代码：002795 证券简称：永和智控 公告编号：2020-039 永和流体智控股份有限公司 关于举办投资者接待日活动的公告 本公司及其董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 永和流体智控股份有限公司（以下简称"公司"）2019 年年度报告已 于 2020 年 3 月 27 日披露，为便于广大投资者深入全面地了解公司经营情 况，公司将于 2019 年年度股东大会召开当日举办投资者接待日活动，现就 有关事项公告如下： 一、活动时间：2020 年 4 月 21 日（星期二）上午 09：30—11：30 二、活动地点：四川省成都市高新区环球中心 W6 2117 号 三、活动方式：现场接待 四、出席人员： 公司董事长曹德莅先生、副总经理兼董事会秘书刘杰先生、财务总监 卢烯权先生、公司独立董事盛毅先生。（如有特殊情况，参会人员会有调 整） 五、预约登记： 请参加本次活动的投资者提前与公司董事会秘书办公室进行预约登记 （节假日除外），以便做好活动接待安排。 （1）登记方式：以现场、电话、传真或邮件的方式进行登记 （2）预约时间：2020 年 4 月 17 日前（9:00-1 ...

证券代码：002795 证券简称：永和智控 公告编号：2019-068 永和流体智控股份有限公司 关于参加浙江辖区上市公司 投资者网上集体接待日活动的公告 本公司及其董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的沟通交流，使广大投资者深入全面地了解永和流体 智控股份有限公司（以下简称"公司"） 的经营情况，公司将参加由中国证监 会浙江监管局指导、浙江上市公司协会与深圳市全景网络有限公司（以下简称"全 景网"）共同举办的"沟通促发展 理性共成长"辖区上市公司投资者网上集体接 待日主题活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过全景网提供的网上平台举行，投资者 可以登录"全景·路演天下"网站（http://rs.p5w.net）参与公司本次投资者 网上接待日活动。网上互动交流时间为 2019 年 11 月 5 日（星期二）下午 15:30-17:00。 届时公司董事兼财务总监吴晚雪女士、董事会秘书姚米娜女士及相关工作人 员将与投资者通过网络在线交流形式就公司治理、经营发展状况等投资者关心的 问题进行沟通与交流（如有特殊情况，参与人员会 ...

永和流体智控股份有限公司 2019 年第三季度报告全文 永和流体智控股份有限公司 2019 年第三季度报告 永和流体智控股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人应雪青、主管会计工作负责人吴晚雪及会计机构负责人(会计主 管人员)陈赛伟声明：保证季度报告中财务报表的真实、准确、完整。 2 永和流体智控股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 2019 年 10 月 1 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 703,669,078.35 | | 757,903,017.47 | -7.16% | | 归属于上市公司股东的净资产 | 605,030,925.75 ...

Financial Performance - The company's operating revenue for the first half of 2019 was ¥301,015,681.21, a decrease of 7.15% compared to ¥324,192,947.41 in the same period last year[17]. - The net profit attributable to shareholders of the listed company increased by 19.45% to ¥38,106,430.13, up from ¥31,901,703.67 in the previous year[17]. - The net cash flow from operating activities surged by 138.10% to ¥79,597,519.54, compared to ¥33,430,890.85 in the same period last year[17]. - Basic earnings per share rose by 19.44% to ¥0.1905, compared to ¥0.1595 in the previous year[17]. - Total assets at the end of the reporting period were ¥698,786,169.04, a decrease of 7.80% from ¥757,903,017.47 at the end of the previous year[17]. - The net assets attributable to shareholders of the listed company decreased by 9.54% to ¥586,138,695.28, down from ¥647,967,559.61 at the end of the previous year[17]. - The gross profit margin improved by approximately 4.34 percentage points to 30.33%, influenced by increased export tax rebates and a decrease in raw material prices[47]. - The total comprehensive income for the first half of 2019 was CNY 38,171,135.67, an increase of 19.9% from CNY 31,798,900.85 in the first half of 2018[154]. Revenue Breakdown - The valve product category generated ¥198,112,559.12, accounting for 65.81% of total revenue, down 7.55% from ¥214,294,821.23[45]. - The pipe fittings category saw a significant decline of 17.61%, with revenue of ¥66,801,820.75 compared to ¥81,082,554.95 in the previous year[45]. - Domestic sales amounted to ¥7,345,336.07, down 14.37% from ¥8,577,710.52, while export sales were ¥293,670,345.14, a decrease of 6.95%[45]. - Sales of copper valves and fittings accounted for approximately 95% of the company's total revenue during the reporting period, indicating a high dependency on this segment[78]. Investment and R&D - The company invested RMB 9.30 million in R&D, representing a 14.13% increase year-on-year[43]. - The company's construction in progress increased by 36.32% compared to the beginning of the year, mainly due to investments in fundraising projects[26]. - The project to add an annual production capacity of 30 million sets of lead-free plumbing fittings has seen an investment of RMB 13,574.5 million, achieving a progress rate of 57.31%[65]. - The valve research and testing center project has received RMB 897.3 million, with a progress rate of 29.50%[65]. Cash Flow and Financing - The cash inflow from operating activities was CNY 342,360,863.30, slightly up from CNY 334,774,800.82 in the first half of 2018[156]. - Cash inflow from investment activities totaled ¥368,361,179.35, while cash outflow was ¥375,693,504.80, resulting in a net cash flow of -¥7,332,325.45, contrasting with a positive net cash flow of ¥3,756,802.34 in the previous year[158]. - The company reported a net cash flow from financing activities of -¥100,000,000.00, compared to -¥18,033,931.42 in the first half of 2018, indicating increased cash outflows for financing[159]. - The company paid ¥100,000,000.00 in dividends, significantly higher than the ¥17,056,310.00 paid in the same period last year, reflecting a strategic decision to return more capital to shareholders[162]. Market and Strategic Initiatives - The company is actively exploring new markets, particularly in Eastern Europe and emerging markets, to offset declines in the U.S. market[40]. - The company has established stable cooperative relationships with global key customers, enhancing its competitive advantage[35]. - The company has upgraded production equipment and implemented automation to improve production efficiency and product quality[41]. - The company has committed to managing policy risks effectively, particularly regarding export tax rebate rates that could affect product costs and profitability[79]. Shareholder and Governance - The company plans not to distribute cash dividends or issue bonus shares[5]. - The controlling shareholder has pledged to increase their shareholding by no less than 1% and no more than 2% of the total share capital within twelve months[91]. - The company has committed that after the lock-up period, the transfer of shares by senior management will not exceed 25% of their total shareholding each year[89]. - The company has not conducted any major litigation or arbitration matters during the reporting period[95]. Risks and Challenges - The main raw material, copper rods, accounts for approximately 60% of production costs, exposing the company to price volatility risks[75]. - The company exports 90% of its products, primarily priced in USD, which subjects it to exchange rate fluctuation risks[76]. - The company faces risks related to the single business focus on fluid control equipment, which could significantly impact performance if the industry experiences major changes[78]. - The fundraising project may face market absorption risks if the global economy or related industries experience significant adverse changes[77]. Compliance and Regulations - The company has complied with environmental laws and has not faced penalties during the reporting period[112]. - The company has not engaged in targeted poverty alleviation work during the reporting period and has no subsequent plans[113]. - The company has not engaged in any related party transactions during the reporting period[101]. - The company has implemented commitments to avoid conflicts of interest and ensure compliance with regulations regarding share transfers and reductions[86].